Search & Analyze

Supriya Lifescience Ltd.

853.30−15.10 (−1.74%)

BSE · 30 Oct, 4:01 PM

: ₹6,810.45 Cr
: 34.33
: 6,074
: ₹880.30 - ₹842.20
: ₹1,085.50 - ₹545.65

Supriya Lifescience Ltd. (SUPRIYA) share price closed at ₹853.30 on the BSE on Friday, October 30, 2026, down by 1.74% from its of ₹868.40. In that session SUPRIYA reached a of 880.30 and of 842.20. The for the session was 856.78. The stands at 874.86 and is at 785.18. Looking at , the stock ended the session in Downtrend.

Stock Overview

₹868.95

₹868.40

₹856.78

₹874.86

Price 2.46% below

₹785.18

Price 8.68% above

Key Fundamentals

: 6,810.45 Cr₹6.81 Thousand Crore
: 24.65
: 34.33
: 5.57
: 151.81
: 301.27 Cr₹301.27 Crore
: 0.12 %
Sector
Industry: Pharmaceuticals & Drugs
: 19.06
: 0.00

Industry Comparison

Ratio	Company	Sector
	34.33	44.48
	0.00	0.10
	5.57	4.89
	4.40	1.97
	0.12 %	0.13 %
Operating Margin	32.24 %	20.36 %

Sector figures are the median of 154 listed Healthcare companies.

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,778.25	129.27	4,26,661.74	0.90	871.29	54.42%	6,141.92	35.04%	13.27
DIVI'S LAB. DIVISLAB	9,715.00	87.69	2,57,902.73	0.31	891.00	59.96%	2,974.00	26.18%	21.89
TORRENT PHAR TORNTPHARM	4,635.15	86.68	1,76,306.21	0.82	498.00	-16.58%	4,145.00	50.07%	19.77
LAURUSLABS LAURUSLABS	2,392.00	123.68	1,29,242.68	0.08	388.13	79.96%	2,014.11	28.57%	16.08
ZYDUSLIFE ZYDUSLIFE	1,244.00	35.31	1,24,089.48	0.08	339.60	-11.72%	2,872.20	10.97%	16.05
DR.REDDY'S DRREDDY	1,350.20	115.98	1,12,698.53	0.59	695.80	79.65%	5,572.60	20.66%	12.67
CIPLA LTD. CIPLA	1,380.00	42.06	1,11,488.55	0.94	787.03	-34.98%	5,067.42	-3.03%	14.04
Supriya Lifescience Ltd. SUPRIYA	853.30	34.33	6,810.45	0.12	24.04	-30.89%	189.75	30.79%	25.30

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	158.18	160.63	166.10	185.65	184.11	145.07	199.83	206.44	276.53	189.75
Expenses	102.68	98.09	101.38	119.69	116.52	93.37	127.19	134.36	178.91	142.29
	55.50	62.54	64.72	65.95	67.59	51.70	72.65	72.08	97.62	47.46
	35.09%	38.94%	38.96%	35.53%	36.71%	35.64%	36.35%	34.92%	35.30%	25.01%
	2.19	2.22	2.52	2.10	2.98	2.67	2.73	2.15	3.48	2.65
Interest	0.60	0.34	0.43	0.51	0.42	0.51	0.42	0.49	0.47	0.37
	3.91	4.66	4.74	4.96	6.08	6.45	6.64	6.82	8.50	8.94
	53.18	59.77	62.06	62.58	64.06	47.41	68.32	66.92	92.13	40.79
	30.55%	25.31%	25.64%	25.24%	21.35%	26.62%	26.19%	25.77%	19.43%	41.06%
	36.93	44.64	46.15	46.78	50.38	34.79	50.43	49.68	74.23	24.04
	4.59	5.55	5.73	5.81	6.26	4.32	6.27	6.17	9.22	2.99

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	588.52	516.47	646.93	781.92	914.72
Less: Excise Duty	58.47	55.53	76.59	85.44	86.85
	530.05	460.94	570.34	696.49	827.88
EXPENDITURE :
Increase/Decrease in Stock	-3.03	-6.51	30.31	-21.26	-11.09
Raw Material Consumed	198.83	187.32	191.43	232.44	265.12
Power & Fuel Cost	14.07	20.95	21.37	24.80	29.77
Employee Cost	49.08	55.58	67.64	80.52	96.68
Other Manufacturing Expenses	19.81	28.71	35.34	50.18	79.59
General and Administration Expenses	11.23	16.73	21.66	27.55	33.18
Selling and Distribution Expenses	22.58	24.16	22.17	34.74	32.50
Miscellaneous Expenses	3.49	5.56	4.73	6.60	7.20
	316.06	332.50	394.65	435.57	532.94
Operating Profit (Excl OI)	213.98	128.44	175.69	260.92	294.93
	7.58	9.94	10.96	9.82	11.49
	221.56	138.39	186.65	270.73	306.42
Interest	4.20	3.08	5.15	1.81	2.77
PBDT	217.36	135.30	181.50	268.92	303.65
	10.12	11.82	15.81	20.44	28.41
Profit Before Taxation & Exceptional Items	207.25	123.49	165.69	248.48	275.24
Exceptional Income / Expenses					-0.46
	207.25	123.49	165.69	248.48	274.78
Provision for Tax	55.44	33.63	46.58	60.52	65.66
	151.81	89.86	119.11	187.96	209.12
Extra items				0.00	0.00
Consolidated Net Profit	151.81	89.86	119.11	187.96	209.12
Profit Balance B/F	253.72	401.13	486.16	600.45	781.97
Appropriations	405.53	490.99	605.28	788.40	991.09
Equity Dividend %	30.00%	30.00%	40.00%	50.00%	50.00%
	18.86	11.16	14.80	23.35	25.98
Adjusted EPS	18.86	11.16	14.80	23.35	25.98

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	16.10	16.10	16.10	16.10	16.10
Total Reserves	599.59	683.36	799.27	980.66	1,181.64
Reserve excluding Revaluation Reserve	599.59	683.36	799.27	980.66	1,181.64
Revaluation reserve		0.00	0.00	0.00
	615.69	699.46	815.37	996.76	1,197.73
Deferred Tax Assets / Liabilities	11.15	13.68	23.15	27.02	31.24
Other Long Term Liabilities	5.30	5.49	5.02	5.06	5.19
Long Term Provisions	2.93	5.88	0.80	1.32	1.90
Total Non-Current Liabilities	19.38	25.04	28.98	33.39	38.33
Trade Payables	48.97	64.23	59.57	74.55	110.85
Other Current Liabilities	22.61	9.50	19.64	11.46	8.53
Short Term Borrowings	21.30	16.63
Short Term Provisions	6.82	5.42	0.37	1.19	1.67
Total Current Liabilities	99.70	95.78	79.57	87.19	121.04
Total Liabilities	734.76	820.28	923.92	1,117.35	1,357.11
Gross Block	222.92	306.49	370.82	534.00	798.69
Less: Accumulated Depreciation	33.14	44.95	60.69	81.13	109.54
	189.77	261.54	310.13	452.87	689.15
	43.41	67.63	148.83	148.02	35.55
Non Current Investments	0.05	25.30	63.80	63.24	98.52
Long Term Investment	0.05	25.30	63.80	63.24	98.52
Long Term Loans & Advances	3.98	0.93	0.68	11.15	1.58
Other Non Current Assets		0.00	0.00	0.00
Total Non-Current Assets	237.22	355.39	523.43	675.28	824.80
Inventories	92.31	115.77	85.25	118.35	159.60
Sundry Debtors	115.18	84.66	111.68	134.36	219.45
Cash and Bank	227.91	157.58	74.96	79.15	78.87
Other Current Assets	13.28	17.26	15.95	10.95	9.25
Short Term Loans and Advances	48.86	89.62	112.65	99.25	65.14
Total Current Assets	497.54	464.89	400.48	442.07	532.30
Net Current Assets (Including Current Investments)	397.84	369.11	320.91	354.88	411.26
Total Assets	734.76	820.28	923.92	1,117.35	1,357.11
	5.62	5.62	3.46	4.17	8.81
Total Debt	21.30	16.63	0.00	0.00	0.00
	76.50	86.91	101.31	123.84	148.81
Adjusted Book Value	76.50	86.91	101.31	123.84	148.81

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	207.25	123.49	165.69	248.48	274.78
Adjustment	6.87	4.61	2.40	13.74	19.89
Changes In working Capital	-104.35	-33.82	-17.14	-38.36	-47.50
Cash Flow after changes in Working Capital	109.76	94.29	150.95	223.85	247.17
Cash Flow from Operating Activities	48.80	63.61	113.31	164.68	185.77
Cash Flow from Investing Activities	-59.82	-123.65	-173.57	-152.24	-176.17
Cash Flow from Financing Activitie	149.65	-10.28	-22.36	-8.23	-9.88
Net Cash Inflow / Outflow	138.63	-70.32	-82.63	4.20	-0.29
Opening Cash & Cash Equivalents	89.28	227.91	157.58	74.96	79.15
Closing Cash & Cash Equivalent	227.91	157.58	74.96	79.15	78.87

Ratios

Valuation

34.33

5.57

22.34

7.81

24.65

151.81

Profitability

19.06

25.30

16.90

32.24

22.86

Leverage & Liquidity

0.00

4.40

100.13

Returns

0.12

0.74

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	68.30	68.30	68.30	68.30	68.30	68.30	68.30	68.30	68.30	68.30
	10.43	11.48	11.44	11.45	11.64	10.68	10.21	10.86	11.49	11.91
	21.27	20.23	20.26	20.26	20.06	21.02	21.50	20.84	20.21	19.79
	31.70	31.70	31.70	31.70	31.70	31.70	31.70	31.70	31.70	31.70
No. of Shareholders	89,621	85,328	89,394	91,051	91,928	87,912	85,099	81,161	82,082	78,561

Mutual Funds Invested(18)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 7 active funds hold 1.19% in Supriya Lifescience Ltd., contributing to ₹91 Cr of holdings

Fund				As of
AB Abakkus Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	51.05	0.65	5,37,227	Sep '26
IT ITI Large & Mid Cap Fund - Growth - Direct PlanLarge & Mid Cap	11.00	1.59	1,15,795	Sep '26
QU Quantum Small Cap Fund - Growth - Direct PlanSmall cap Fund	10.38	3.97	1,09,252	Sep '26
IT ITI ELSS Tax Saver Fund - Growth - Direct PlanEquity - ELSS - Tax Saver Fund	8.70	1.96	91,519	Sep '26
MO Motilal Oswal Nifty Microcap 250 Index Fund - Growth - Direct PlanIndex Funds - Other	6.58	0.27	69,241	Sep '26
WC WhiteOak Capital Pharma and Healthcare Fund - Growth - Direct PlanPharma & Health Care	6.43	0.69	67,618	Sep '26
IT ITI Pharma & Healthcare Fund - Growth - Direct PlanPharma & Health Care	2.66	1.00	27,984	Sep '26
QU Quantum Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	0.62	0.96	6,531	Sep '26
MO Motilal Oswal BSE Healthcare ETFIndex	0.07	0.15	718	Sep '26
AO Angel One Nifty Total Market Momentum Quality 50 Index Fund - Growth - Direct PlanIndex Funds - Other	0.06	0.16	598	Sep '26

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-09-02	AGM
2026-08-06	Board Meeting	Quarterly Results
2026-05-27	Ex Dividend	Rs.1.0000 per share(50%)Final Dividend	2026-09-04	2026-09-04

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Supriya Lifescience Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

12 members across the board and senior leadership

Satish Waman Wagh

Chairman

₹12.00 Cr

Mar '26

Saloni Satish Wagh

Managing Director

₹3.40 Cr

Mar '26

Shivani Satish Wagh

Joint Managing Director

₹3.40 Cr

Mar '26

Smita Satish Wagh

Whole Time Director

₹1.76 Cr

Mar '26

Balasaheb Gulabrao Sawant

Whole Time Director

₹75.63 L

Mar '26

Manish Panchal

Non Executive Independent Director

₹40,000

Mar '26

Hari K

Non Executive Independent Director

₹40,000

Mar '26

Neelam Yashpal Arora

Non Executive Independent Director

₹1.20 L

Mar '26

Ganapati Dadasaheb Yadav

Non Executive Independent Director

₹2.60 L

Mar '26

Sunil Subhash Bhagwat

Non Executive Independent Director

₹1.50 L

Mar '26

Prachi Sathe

Company Secretary & Compliance Officer

—

Kothandaraman Hari

Non Executive Independent Director

—

SUPRIYA Latest News

News

6 of 6 articles

EQUITY19 Oct 2026 · 11:15

Supriya Lifescience informs about further update on judicial proceedings

EQUITY14 Oct 2026 · 10:05

Supriya Lifescience informs about ESG ratings

EQUITY23 Sept 2026 · 15:06

Supriya Lifescience informs about updates

EQUITY23 Jul 2026 · 11:12

Supriya Lifescience informs about newspaper advertisement

EQUITY15 Jun 2026 · 16:42

Supriya Lifescience informs about analyst meet

EQUITY27 May 2026 · 18:41

Supriya Lifescience reports Profit after tax of Rs 742.29 Mln, in the March 2026 quarter

Supriya Lifescience Ltd.

Stock Overview

Price chart

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Valuation

Profitability

Leverage & Liquidity

Returns

Shareholding Pattern

Mutual Funds Invested(18)

Corporate Actions

Insider Trading

Sector Overview

Company Profile

Key Management

SUPRIYA Latest News

News